Nuclear upregulation of class I phosphoinositide 3-kinase p110β correlates with high 47S rRNA levels in cancer cells.


Journal

Journal of cell science
ISSN: 1477-9137
Titre abrégé: J Cell Sci
Pays: England
ID NLM: 0052457

Informations de publication

Date de publication:
10 02 2021
Historique:
received: 01 04 2020
accepted: 24 12 2020
pubmed: 5 2 2021
medline: 13 7 2021
entrez: 4 2 2021
Statut: epublish

Résumé

The class I phosphoinositide 3-kinase (PI3K) catalytic subunits p110α and p110β are ubiquitously expressed but differently targeted in tumours. In cancer,

Identifiants

pubmed: 33536247
pii: jcs.246090
doi: 10.1242/jcs.246090
pii:
doi:

Substances chimiques

Phosphatidylinositol 3-Kinase EC 2.7.1.137

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© 2021. Published by The Company of Biologists Ltd.

Déclaration de conflit d'intérêts

Competing interestsThe authors declare no competing or financial interests.

Auteurs

Fatemeh Mazloumi Gavgani (F)

Department of Biological Sciences, University of Bergen, Bergen 5008, Norway.

Thomas Karlsson (T)

Department of Biological Sciences, University of Bergen, Bergen 5008, Norway.

Ingvild L Tangen (IL)

Centre for Cancer Biomarkers, Department of Clinical Science, University of Bergen, Bergen 5021, Norway.
Department of Gynaecology and Obstetrics, Haukeland University Hospital, Bergen 5021, Norway.

Andrea Papdiné Morovicz (AP)

Department of Biological Sciences, University of Bergen, Bergen 5008, Norway.

Victoria Smith Arnesen (VS)

Department of Biological Sciences, University of Bergen, Bergen 5008, Norway.

Diana C Turcu (DC)

Department of Biological Sciences, University of Bergen, Bergen 5008, Norway.

Sandra Ninzima (S)

Department of Biological Sciences, University of Bergen, Bergen 5008, Norway.

Katharina Spang (K)

Department of Biological Sciences, University of Bergen, Bergen 5008, Norway.

Camilla Krakstad (C)

Centre for Cancer Biomarkers, Department of Clinical Science, University of Bergen, Bergen 5021, Norway.
Department of Gynaecology and Obstetrics, Haukeland University Hospital, Bergen 5021, Norway.

Julie Guillermet-Guibert (J)

Inserm U1037, Centre de Recherches en Cancérologie de Toulouse (CRCT), Institut National de la Santé et de la Recherche Médicale (INSERM), Université Toulouse III Paul Sabatier, 31037 Toulouse, France.

Aurélia E Lewis (AE)

Department of Biological Sciences, University of Bergen, Bergen 5008, Norway aurelia.lewis@uib.no.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH